Amiodarone
- TRADE NAMES: Aratac; Corbionax; Cordarex; Cordarone (Wyeth); Cordarone X; Pacerone (Upsher-Smith); Tachydaron
- INDICATIONS: Ventricular fibrillation, ventricular tachycardia
- CLASS: Antiarrhythmic, Antiarrhythmic class III, CYP1A2 inhibitor, CYP3A4 inhibitor
- HALF-LIFE: 26–107 days
Abarelix, Acebutolol, Acenocoumarol, Afatinib, Amisulpride, Amitriptyline, Amprenavir, Anisindione, Anticoagulants, Arsenic, Artemether/Lumefantrine, Asenapine, Astemizole, Atazanavir, Atorvastatin, Azoles, Betrixaban, Boceprevir, Bosentan, Carbimazole, Celiprolol, Cholestyramine, Cimetidine, Ciprofloxacin, Clopidogrel, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Colchicine, Cyclosporine, Dabigatran, Daclatasvir, Darunavir, Degarelix, Delavirdine, Dextromethorphan, Dicumarol, Digoxin, Diltiazem, Disopyramide, Dronedarone, Droperidol, Echinacea, Enoxacin, Fentanyl, Finerenone, Flecainide, Fosamprenavir, Gatifloxacin, Grapefruit Juice, Indinavir, Ledipasvir & Sofosbuvir, Lesinurad, Letermovir, Levofloxacin, Levomepromazine, Lidocaine, Lomefloxacin, Lopinavir, Loratadine, Macrolide antibiotics, Methotrexate, Moxifloxacin, Naldemedine, Nelfinavir, Nevirapine, Nilotinib, Norfloxacin, Ofloxacin, Orlistat, Oxprenolol, Pentamidine, Phenytoin, Pimavanserin, Ponesimod, Procainamide, Propranolol, Quinidine, Quinine, Quinolones, Ribociclib, Rifabutin, Rifampin, Rifapentine, Ritonavir, Ropivacaine, Rosuvastatin, Simvastatin, Sofosbuvir & Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Sotalol, Sparfloxacin, St John's Wort, Sulpiride, Tacrolimus, Talazoparib, Telaprevir, Tetrabenazine, Thalidomide, Tipranavir, Trazodone, Vandetanib, Venetoclax, Verapamil, Warfarin, Zuclopenthixol
PREGNANCY CATEGORY: D
Amiodarone induced pulmonary toxicity has an incidence of about 5%-10%, and it is considered the most serious adverse effect with mortalities reaching up to 10% of the patients.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of amiodarone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/30/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
